Secukinumab
REQUEST MORE INFO
Price:
US$464.00
(Size: 100 µg)
Click on the image to see the image legend
Secukinumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL17A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Secukinumab (Cosentyx) is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and Drug Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis.
Target |
IL17A |
Clonality |
Monoclonal |
Reactivity |
Human |
Expression |
Recombinant |
Tested Applications |
ELISA, WB |
Host |
Human |
Recommended dilutions |
Optimal dilutions/concentrations should be determined by the end user. |
Conjugation |
Unconjugated |
Isotype |
IgG1 Kappa |
Form |
Liquid |
Purity |
> 95% |
Purification |
Purified from cell culture supernatants by Protein A/G chromatography. |
Storage |
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Buffer |
0.01 M PBS. pH 7.4. |
CAS Number |
1229022-83-6 |
Concentration |
Batch-dependent, typically between 0.5-2.0 mg/ml. |
Availability |
Shipped within 7-12 working days. |
Note |
This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Research Articles on IL17A